Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol reconsolidation intervention for panic symptoms in burnout
NL-OMON51177Active, not recruiting
- Sponsor
- TNO
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of propranolol in panic disorder and burnout syndrome, sponsored by TNO. Primary endpoint: Decrease in frequency and severity of panic symptoms. Started Jun 2022; status: active, not recruiting.
02
Drugs
propranolol
03
Conditions
panic disorderburnout syndrome
Beyond the preview
Go deeper on NL-OMON51177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51177.